Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register
(2011) In Annals of the Rheumatic Diseases 70(3). p.516-519- Abstract
- Objective To determine coverage and generalisability of data in the Swedish Biologics Register ARTIS. Methods Patients with adult onset rheumatoid arthritis (RA) were identified in the National Patient Register and the Swedish Rheumatology Quality Register, including the ARTIS cohort of patients exposed to biological agents. Exposure to etanercept and adalimumab between 2006 and 2008 was determined by register linkage to the Prescribed Drug Register which contains patient-level data on >99% of all etanercept and adalimumab use in Sweden. Results Of 62 897 patients with RA, 6510 had received treatment with etanercept or adalimumab according to the Prescribed Drug Register. Of these, 5673 were also registered in ARTIS, resulting in a... (More)
- Objective To determine coverage and generalisability of data in the Swedish Biologics Register ARTIS. Methods Patients with adult onset rheumatoid arthritis (RA) were identified in the National Patient Register and the Swedish Rheumatology Quality Register, including the ARTIS cohort of patients exposed to biological agents. Exposure to etanercept and adalimumab between 2006 and 2008 was determined by register linkage to the Prescribed Drug Register which contains patient-level data on >99% of all etanercept and adalimumab use in Sweden. Results Of 62 897 patients with RA, 6510 had received treatment with etanercept or adalimumab according to the Prescribed Drug Register. Of these, 5673 were also registered in ARTIS, resulting in a national coverage of 87%. The regional variation was small with >85% coverage in 18 of 21 counties. In multivariable analysis, ARTIS-registered and non-registered patients did not differ by age (p=0.62), sex (p=0.84) or education level (p=0.24). Conclusion Nationwide drug dispensing and demographic data may function as quality metrics for coverage and generalisability assessments. Using such data, the coverage of ARTIS was estimated at 87% with no indications of compromised external generalisability regarding demography. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1876645
- author
- Neovius, M. ; Simard, J. F. ; Sundstrom, A. ; Jacobsson, L ; Geborek, Pierre LU ; Saxne, Tore LU ; Feltelius, N. ; Klareskog, L. and Askling, J.
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 70
- issue
- 3
- pages
- 516 - 519
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000286927800019
- scopus:79951472502
- pmid:21081525
- ISSN
- 1468-2060
- DOI
- 10.1136/ard.2010.130914
- language
- English
- LU publication?
- yes
- id
- 7ed26ffb-2463-4ab3-a2e0-d936f3f1381b (old id 1876645)
- date added to LUP
- 2016-04-01 13:39:37
- date last changed
- 2022-02-26 22:20:19
@article{7ed26ffb-2463-4ab3-a2e0-d936f3f1381b,
abstract = {{Objective To determine coverage and generalisability of data in the Swedish Biologics Register ARTIS. Methods Patients with adult onset rheumatoid arthritis (RA) were identified in the National Patient Register and the Swedish Rheumatology Quality Register, including the ARTIS cohort of patients exposed to biological agents. Exposure to etanercept and adalimumab between 2006 and 2008 was determined by register linkage to the Prescribed Drug Register which contains patient-level data on >99% of all etanercept and adalimumab use in Sweden. Results Of 62 897 patients with RA, 6510 had received treatment with etanercept or adalimumab according to the Prescribed Drug Register. Of these, 5673 were also registered in ARTIS, resulting in a national coverage of 87%. The regional variation was small with >85% coverage in 18 of 21 counties. In multivariable analysis, ARTIS-registered and non-registered patients did not differ by age (p=0.62), sex (p=0.84) or education level (p=0.24). Conclusion Nationwide drug dispensing and demographic data may function as quality metrics for coverage and generalisability assessments. Using such data, the coverage of ARTIS was estimated at 87% with no indications of compromised external generalisability regarding demography.}},
author = {{Neovius, M. and Simard, J. F. and Sundstrom, A. and Jacobsson, L and Geborek, Pierre and Saxne, Tore and Feltelius, N. and Klareskog, L. and Askling, J.}},
issn = {{1468-2060}},
language = {{eng}},
number = {{3}},
pages = {{516--519}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register}},
url = {{http://dx.doi.org/10.1136/ard.2010.130914}},
doi = {{10.1136/ard.2010.130914}},
volume = {{70}},
year = {{2011}},
}